潰瘍性大腸炎および関連する不安症におけるハイパーソイドの微生物群主導の治療効果
Li Yin1, Lin Xu2, Yu-Nan Shan3
1Department of Gastroenterology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Frontiers in cellular and infection microbiology
|February 16, 2026
まとめ
ハイパーソイド (HYP) は,腸内微生物群を回復し,重要なシグナル伝達経路を調節することにより,潰瘍性大腸炎 (UC) と不安を効果的に治療します. UCおよび関連する不安に対する治療効果は,健康な腸内微生物群に依存しています.
科学分野:
- 胃腸内科 胃腸内科
- 神経科学は神経科学である.
- 微生物学 微生物学とは
背景:
- 潰瘍性大腸炎 (UC) は炎症性腸疾患で,しばしば不安障害と併発しますが,有効な二重標的治療は限られています.
- ハイパーソイド (HYP) は天然のフラボノイドで,抗炎症および神経保護性があります.
- UCと併発性不安に対するHYPの治療的可能性は,そのメカニズムを含む,ほとんど未知のままです.
研究 の 目的:
- ハイパーソイド (HYP) がデクストラン硫酸ナトリウム (DSS) 誘発性潰瘍性大腸炎 (UC) およびそれに関連する不安のような行動に及ぼす治療効果をマウスモデルで調査する.
- HYPの作用の根本的なメカニズムを明らかにし,腸内微生物群,神経炎症,特定のシグナル伝達経路に焦点を当てた.
主な方法:
- マウスにおけるDSS誘発性大腸炎モデルを確立し,HYP.で治療した.
- 大腸炎の重度,不安のような行動,神経炎症 (BDNF,マイクログリア活性化),腸内微生物群の構成,宿主の代謝を評価した.
- 信号伝達経路 (MAPK,PI3K-Akt,NF-κB) を特定および検証するために,ネットワーク薬理学,分子ドッキング,およびウエスタン・ブロッティングを使用しました.
- 微生物群の依存性を確認するために,抗生物質の枯渇実験を行いました.
主要な成果:
- HYPは,大腸炎の症状と不安のような行動を大幅に改善しました.
- HYPは,炎症誘発性サイトカインを抑制し,腸内バリアの完全性を回復し,BDNFレベルを上昇させ,マイクログリアル活性化を低下させた.
- HYP治療は腸内微生物群を正常化し,有益な細菌を豊かにし,アルギニンの生合成を促進し,MAPK/PI3K-Akt/NF-κB経路を調節しました.
- 微生物群が枯渇したマウスでは,治療効果は廃止された.
結論:
- ハイパーソイド (HYP) は,DSS誘発性大腸炎と併発性不安のような行動を効果的に軽減します.
- HYPの有効性は腸内微生物群に依存し,微生物の恒常性の回復,アルギニン代謝の強化,MAPK/PI3K-Akt/NF-κB信号伝達の調節を含む.
- HYPは,UCおよびその神経精神病的併合疾患に対する有望な微生物群を標的とした治療候補である.
関連する概念動画
Drugs for Treatment of Ulcerative Colitis in IBD
544
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
544
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.4K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.4K
Drugs for Treatment of Diarrhea-Predominant IBS
754
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
754
Irritable Bowel Syndrome I: Introduction
1.2K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.2K
Peptic Ulcer Disease IV: Management
546
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
546


